Xbrane Biopharma AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 58.89 million compared to SEK 14.1 million a year ago. Net loss was SEK 81.23 million compared to SEK 41.88 million a year ago. Basic loss per share from continuing operations was SEK 2.77 compared to SEK 1.69 a year ago. Diluted loss per share from continuing operations was SEK 2.77 compared to SEK 1.69 a year ago. Basic loss per share was SEK 2.78 compared to SEK 1.67 a year ago. Diluted loss per share was SEK 2.78 compared to SEK 1.67 a year ago.
For the nine months, sales was SEK 171.84 million compared to SEK 40.31 million a year ago. Net loss was SEK 230.64 million compared to SEK 111.78 million a year ago. Basic loss per share from continuing operations was SEK 8.1 compared to SEK 4.51 a year ago. Diluted loss per share from continuing operations was SEK 8.1 compared to SEK 4.51 a year ago. Basic loss per share was SEK 8.14 compared to SEK 4.45 a year ago. Diluted loss per share was SEK 8.14 compared to SEK 4.45 a year ago.